Anuh Pharma Ltd Valuation Shifts: From Attractive to Fair Amid Sector Comparisons

Valuation Metrics and Recent Changes

As of 1 June 2026, Anuh Pharma’s P/E ratio stands at 18.58, a figure that has contributed to its revised valuation grade from attractive to fair. This P/E multiple, while moderate, is significantly lower than several of its peers, many of whom are classified as very expensive or expensive. For instance, Bliss GVS Pharma and Kwality Pharma trade at P/E ratios of 34.63 and 35.73 respectively, underscoring Anuh Pharma’s relative valuation advantage within the sector.

The company’s price-to-book value ratio is currently 2.17, which aligns with its fair valuation status. This P/BV is slightly higher than some peers like Venus Remedies (1.68) but remains below the levels seen in more richly valued companies such as NGL Fine Chem and Jagsonpal Pharma, which have P/BV ratios well above 3.0. The enterprise value to EBITDA (EV/EBITDA) multiple of 11.60 further supports the fair valuation narrative, positioning Anuh Pharma in a more reasonable valuation bracket compared to peers like Ind-Swift Laboratories, which trades at an EV/EBITDA of 30.92.

Financial Performance and Returns Context

Despite the valuation shift, Anuh Pharma’s operational metrics remain robust. The company’s return on capital employed (ROCE) is a healthy 16.65%, while return on equity (ROE) is 11.65%, indicating efficient capital utilisation and profitability. Dividend yield at 1.97% adds a modest income component for investors, though it is not a primary driver of valuation.

From a price performance perspective, Anuh Pharma has delivered mixed returns relative to the benchmark Sensex. Over the past week, the stock gained 1.02%, outperforming the Sensex’s decline of 0.85%. However, on a one-month basis, the stock declined 6.35%, underperforming the Sensex’s 3.51% fall. Year-to-date, Anuh Pharma’s loss of 4.46% is less severe than the Sensex’s 12.26% drop, reflecting some resilience amid broader market weakness.

Longer-term returns paint a more favourable picture, with the stock delivering a 74.55% gain over three years, significantly outpacing the Sensex’s 18.98% rise. Over ten years, however, the stock’s 53.40% appreciation lags the Sensex’s 180.55%, highlighting the challenges of sustaining outperformance over extended periods.

Peer Comparison and Relative Valuation

When benchmarked against its pharmaceutical peers, Anuh Pharma’s valuation appears more reasonable, though the shift to a fair grade signals a narrowing margin of safety for investors. Companies such as Venus Remedies and Fredun Pharma maintain attractive valuations with P/E ratios of 16.68 and 36.23 respectively, but Fredun’s higher P/E is offset by a lower EV/EBITDA of 15.97, suggesting differing market expectations on growth and profitability.

Conversely, several peers are trading at very expensive valuations, including Bliss GVS Pharma (P/E 34.63, EV/EBITDA 26.69) and Jagsonpal Pharma (P/E 30.37, EV/EBITDA 20.75), which may reflect higher growth prospects or investor enthusiasm. Anuh Pharma’s more moderate multiples could indicate a more cautious market stance, possibly due to its micro-cap status and associated liquidity and risk considerations.

The PEG ratio for Anuh Pharma is reported as zero, which may indicate a lack of consensus on earnings growth projections or data unavailability. This contrasts with peers like Bliss GVS Pharma (PEG 0.64) and Venus Remedies (PEG 0.10), where growth expectations are factored into valuations. Investors should consider this when assessing the stock’s forward-looking attractiveness.

Price Movement and Market Capitalisation

Anuh Pharma’s current market price is ₹76.89, marginally up 0.26% from the previous close of ₹76.69. The stock’s 52-week trading range spans from ₹66.72 to ₹115.00, indicating significant volatility and a potential upside of over 49% from the current price to the high. However, the recent price action suggests consolidation near the lower end of this range, which may reflect investor caution amid valuation re-rating.

As a micro-cap entity, Anuh Pharma faces inherent challenges including lower liquidity and higher volatility compared to larger pharmaceutical companies. This status is reflected in its market cap grade and contributes to the cautious valuation stance adopted by analysts and investors alike.

Outlook and Investment Considerations

The downgrade in valuation grade from attractive to fair for Anuh Pharma Ltd signals a more cautious outlook from market participants. While the company’s operational metrics such as ROCE and ROE remain solid, the relative valuation compression suggests that investors are factoring in risks related to growth sustainability, competitive pressures, and micro-cap volatility.

Investors should weigh the stock’s moderate valuation multiples against its historical performance and sector peers. The stock’s three-year return of 74.55% significantly outperforms the Sensex, indicating strong past performance, but the one-year loss of 28.06% and the recent valuation shift highlight near-term challenges.

Given the current market environment and Anuh Pharma’s valuation profile, a cautious stance is warranted. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may consider peers with more attractive valuations or stronger growth visibility, while monitoring Anuh Pharma’s earnings trajectory and market developments closely.

In summary, Anuh Pharma’s transition from an attractive to a fair valuation grade reflects a recalibration of price attractiveness amid evolving sector dynamics and peer valuations. The stock remains reasonably priced relative to many expensive peers but faces headwinds that temper enthusiasm. A balanced approach, incorporating both valuation and fundamental analysis, is advisable for prospective investors.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today